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Abstract
Diabetic neuropathy (DN), the most common complication of diabetes, frequently leads to foot 
ulcers and may progress to limb amputations. Despite continuous increase in incidence, there is no 
clinical therapy to effectively treat DN. Pathogenetically, DN is characterized by reduced 
vascularity in peripheral nerves and deficiency in angiogenic and neurotrophic factors. We will 
briefly review the pathogenetic mechanism of DN and address the effects and the mechanisms of 
cell therapies for DN. To reverse the changes of DN, studies have attempted to deliver 
neurotrophic or angiogenic factors for treatment in the form of protein or gene therapy; however, 
the effects turned out to be very modest if not ineffective. Recent studies have demonstrated that 
bone marrow (BM)-derived cells such as mononuclear cells or endothelial progenitor cells (EPCs) 
can effectively treat various cardiovascular diseases through their paracrine effects. As BM-
derived cells include multiple angiogenic and neurotrophic cytokines, these cells were used for 
treating experimental DN and found to reverse manifestations of DN. Particularly, EPCs were 
shown to exert favorable therapeutic effects through enhanced neural neovascularization and 
neuro-protective effects. These findings clearly indicate that DN is a complex disorder with 
pathogenetic involvement of both vascular and neural components. Studies have shown that cell 
therapies targeting both vascular and neural elements are shown to be advantageous in treating 
DN.
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Introduction
Diabetic neuropathy (DN) is a peripheral nervous system disorder and the most common 
complication of diabetes mellitus. There are 23.6 million children and adults in the United 
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States (around 8% of the population) who have diabetes. DN affects up to 60% of long-
standing diabetic patients [1]. Patients afflicted with DN experience decreased quality of life 
due to chronic pain, loss of sensation in the feet and other areas of the body, and chronic 
wounds partly caused by impaired pain response [2]. Autonomic nerve dysfunction also 
contributes to deterioration of the quality of life in diabetic patients [3].
DN can affect sensory, motor and autonomic nerve fibers in any part of the body. The 
nerves of the lower extremities usually become symptomatic first because they have the 
longest nerve fibers. There are several distinct syndromes based on the organ systems and 
types of nerves affected. A patient may have exclusively sensorimotor or autonomic 
neuropathy or a combination of both. Symptoms develop gradually over time and correlate 
with the degree of hyperglycemia.
Currently, there are no clinically validated, curative treatments for DN. Optimization of 
glucose control and foot care may halt disease progression but they cannot reverse nerve 
damages which often lead to debilitating secondary complications over time. Symptomatic 
treatment with pain medications is only partially effective and wounds are difficult to treat. 
Moreover, deficiency of neurotrophic factors has been regarded as one of the likely 
mechanisms underlying DN [1, 4]. In a clinical trial, a single treatment of injected 
neurotrophic cytokines was ineffective for treating DN [5]. Since DN lack both angiogenic 
and neurotrophic factors, cell therapy has recently emerged as an attractive therapeutic 
strategy in DN.
Pathogenetic Mechanisms Underlying DN
Although DN has been widely explored over the past 20 years [6] and its pathology has been 
well established, the pathogenesis remains unclear [7]. Pathological findings reported in 
diabetic patients include axonal atrophy, demyelination, nerve fiber loss, and blunted 
regeneration of nerves [1, 6]. The pathogenesis of DN is multi-factorial, involving both 
metabolic and vascular components [8, 9]. On a molecular level, the primary risk factor is 
hyperglycemia, which is associated with five pathways: the polyol pathway [10]; the 
advanced glycation end-product pathway [11, 12]; the protein kinase C pathway [13]; the 
poly ADP-ribose polymerase (PARP) pathway [14, 15]; and the hexosamine pathway [16]. 
The five pathways contribute to the production of oxidative stress. Accumulation of reactive 
oxygen species (ROS) increases lipid, DNA, and protein peroxidation, induces cellular 
apoptosis and, and reduces nerve blood flow [17, 18]. Increased oxidative stress leads to 
activation of the PARP pathway [19], which regulates the gene expressions involved in 
inflammatory reactions and neuronal dysfunction. Several studies suggest that oxidative 
stress and these five pathways are interdependent and central to the pathogenesis of 
neurovascular dysfunction [20-22].
On a cellular level, hyperglycemia affects sensory, motor, and autonomic neurons by 
activating the five pathways [1, 23]. Moreover, the induction of microvascular ischemia by 
reducing blood flow results in nerve dysfunction. ROS and reactive nitrogen species are 
associated with microvascular complications of diabetes [24-28]. ROS also contributes to 
impaired vasodilation of epineural blood vessels, resulting in ischemia to the neural tissue 
[29-31]. Oxidative stress leads to deterioration of Schwann cells, which play a key role as a 
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provider of insulation for neurons, immunologic perineurial blood-nerve-barrier, and 
effector of nerve regeneration. Such dysfunction via oxidative stress contributes to the 
phenotype of DN. Thus, antioxidants have become the therapeutic targets in DN studies. 
However, only a few studies have suggested that antioxidants can prevent or reverse 
hyperglycemia-induced nerve dysfunction in experimental DN models [32, 33].
Deficiency of Neurotrophic Factors and Vascular Supply as a Cause of DN
In addition to the classical pathogenesis mentioned above, studies have elucidated the major 
pathophysiologic role of neurotrophic factors and vascular supply in DN. The loss of 
neurotrophic support and ischemic hypoxia are widely considered to represent the two 
downstream consequences of the cellular mechanisms described above.
Changes in Growth Factors as a Cause for DN—Many representative growth factors 
have dual effects of being both neurotrophic and angiogenic [34]. Some examples are 
vascular endothelial growth factor (VEGF) [35], insulin-like growth factor (IGF) [36-38], 
nerve growth factor (NGF) [39-41], brain-derived neurotrophic factor (BDNF) [42, 43], and 
fibroblast growth factor-2 (FGF2) [44, 45]. Recently, the term angioneurin was coined to 
refer to a growth factor which have both angiogenic and direct neurotrophic effects [46]. 
The levels of these angioneurins were decreased in diabetic animals and were associated 
with neural function [47, 48].
VEGF, a major angiogenic factor, is a potent selective mitogenic cytokine for endothelial 
cells and its expression can be induced by hypoxia through hypoxia-inducible factor-1 [49]. 
In ischemic tissues, VEGF induces angiogenesis by stimulating the proliferation and 
migration of endothelial cells [50], leading to the improvement of tissue ischemia. VEGF 
also enhances Schwann cell migration [51] and proliferation, promotes axonal outgrowth 
and survival of both the neurons and Schwann cells of superior cervical ganglia and dorsal 
root ganglia [52]. IGFs induce vessel remodeling [38] and also have neurotrophic effect. 
IGFs have been shown to promote neurite outgrowth of neuroblastoma cells [53, 54] and 
accelerate regeneration of sensory [55] and motor nerves [56]. IGF1 is widely expressed in 
craniofacial sensory ganglia, sciatic nerve, spinal cord, sensory dorsal root ganglia and 
brain. IGF2 is expressed in the brain, vascular structures of the nervous system, and motor 
neurons. In neuronal cell bodies, axons and nerve terminals, IGF receptors (IGF1R and 
IGF2R) are present and IGF-1 expression is reduced in streptozotocin-induced diabetic rats 
compared to non-diabetic controls. mRNA and protein expression of both IGF1 and IGF2 is 
decreased in the nerves of streptozotocin-induced diabetic rats and there is also decrease in 
the mRNA and protein expression level of IGF1R in the superior cervical ganglia of 
streptozotocin-diabetic rats [57]. Also, Schwann cell mitogenesis and myelination are 
stimulated by IGF1 [58]. These effects may be important for inter-neuronal signaling and 
peripheral nervous system function. Sonic hedgehog (SHh) modulates patterning and 
development of embryonic nervous system. In diabetic animal, SHh mRNA levels are 
significantly decreased in peripheral nerves. In addition, overexpression of SHh improves 
blood flow to ischemic nerve and ameliorates nerve function [59]. NGF, a well-known 
neurotrophic factor, was initially identified as a molecule that promoted survival and 
differentiation of sensory and sympathetic neurons. Now, NGF has been shown to subserve 
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neuroprotective and repair functions [60]. NGF is synthesized by Schwann cells and target 
cells of sensory and sympathetic neurons such as epithelial cells, smooth muscle cells, and 
fibroblasts [61]. NGF homozygous knockout mice do not develop proper sympathetic 
neurons or small neural crest-derived sensory neurons [62]. In addition to these neurotrophic 
effects, NGF directly induces angiogenesis [40].
Vascular Deficiency as a Cause for DN—Maintaining adequate blood supply to 
nerves is crucial in maintaining nerve structure and function. Deficiencies in the blood 
supply to neural tissues through vasa nervorum, blood vessel within peripheral nerves 
largely contribute to pathogenetic mechanism of DN [63]. Several mechanisms on vascular 
structural changes in ischemia on diabetic nerve have been proposed. The most common 
abnormality in the structure of diabetic vasa nervora is the thickening of basement 
membrane [64-69], which is highly correlated with neuropathic severity [64, 70, 71]. In 
addition, decrease in nerve conduction velocity (NCV) in diabetic rats is preceded by 
impaired vasodilation in epineurial arterioles, which is partly mediated by ROS production 
[29-31]. In contrast to constricted epineurial arteriole, endoneurial capillaries appear to have 
a variable patency. Luminal areas of endoneurial capillaries were increased in rodent [72-74] 
and feline [75] models of DN, whereas those in human showed mixed results of being 
increased [64, 66, 76], unchanged [65, 69, 77], or decreased [67, 68, 70, 78, 79].
Also, mixed reports on blood vessel number or density in the nerves of diabetic subjects are 
apparently conflicting. In animal models of diabetes, endoneurial capillary density was 
reported to be increased [74, 80], unaltered [81], or decreased [47, 48, 82]. In human, the 
endoneurial capillary density was reported to be higher in early diabetic patients than 
healthy subjects [77]. Conversely, the endoneurial capillary density in diabetic patients with 
established neuropathy, showed no significant difference to that of healthy subjects [64, 65, 
70]. However, recent studies have showed decreased functional capillary density using lectin 
perfusion as a method for measuring capillary density [47, 48, 82]. This discrepancy in the 
number of endoneurial capillaries appears to result from what methods or markers were used 
to examine capillaries. Studies altogether suggest that the number of capillary increases as 
compensatory response to ischemia in early diabetic condition and decreases, particularly 
the functional capillaries, due to impaired neovascularization under prolonged diabetic 
condition [72, 83, 84].
Despite some controversy on the structural aspects, it appears clear that DN is accompanied 
by ischemia and hypoxia of microcirculatory nutrient vessels in nerves [22, 63]. Because 
microcirculation is regulated by humoral, endothelial and neural factors, a vicious 
pathogenic cycle may develop: microcirculatory dysfunction results in peripheral nerve 
dysfunction which in turn results in abnormal regulation of the microcirculation leading to 
further nerve dysfunction. The reduction in endoneurial blood flow has been shown to be 
ameliorated by treatment with various vasodilatory agents, such as prostaglandin E1 
analogues, alpha-adrenergic receptor blockers, angiotensin-converting enzyme inhibitors, 
angiotensin II receptor antagonists and endothelin receptor antagonists [73, 85-89] in animal 
models of diabetes.
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Further evidence for the impaired vascularization and ischemia in DN are provided by the 
finding that there is a decrease in factors that promote or maintain blood vessel formation in 
DN (such as VEGFs, angiopoietins, IGFs, NGF). These observations led to studies of local 
delivery of the angiogenic factors VEGF-A and VEGF-C into diabetic rats which showed 
increased vasa nervora density and NCVs [63]. Additionally, VEGFs have direct 
neurotrophic effects which may underlie improvement of NCVs. For instance, angiogenic 
medications such as statins have also been shown to improve nerve function in DN [90].
Potential Therapies for DN
Several possible therapies exist for the treatment of DN based on neurovascular 
pathogenesis. Among them are gene, protein, and cell therapies.
Gene and Protein Transfer—Growth factors are attractive therapeutic option for DN 
because they can promote neuron survival and functional integrity, as well as repair of 
damaged nerves. Some growth factors are angiogenic, and their therapeutic effects are 
mediated by blood vessel growth that supply nutrients and oxygen to nerves [91]. Other 
growth factors, such as neutrophin 3, are neurotrophic, and their therapeutic effects are via 
promoting neural regeneration and survival [92]. Growth factors, known as angioneurins 
(VEGF, FGF2, NGF, BDNF, IGF1), have both angiogenic and neurotrophic properties [46]. 
The power of these growth factors in the treatment of DN was shown by Schratzberger et 
al., [51, 63]. They were the first to inject VEGF encoding plasmids into rat and rabbit 
models of diabetes. The VEGF-treated animals showed normalization in NCV, increase in 
angiogenesis of vasa nervora, and increase in nerve fiber density. When the plasmid VEGF 
was applied to human patients, mild, but statistically significant symptomatic improvement 
was observed in a randomized, double-blinded trial [93]. However, the authors also reported 
that VEGF therapy was associated with adverse side effects that did not reach statistical 
significance. As this study has a relatively small sample size, further study is required to 
conclusively determine the effects of plasmid VEGF therapy. Other growth factors, such as 
IGF1 and IGF2 have also been studied in animal models of DN and have shown protective 
effects against development of neuropathy independent of changes in blood glucose [37]. 
The neurotrophic factor, FGF2 promotes angiogenesis and neurogenesis [94]. Diabetic rats 
treated with recombinant FGF2 showed improved nerve blood flow, motor NCV and 
response to mechanical stimuli 30 day post-injection. These results suggest that FGF2 
supplementation is a potential therapeutic target of DN [95].
However, most of human clinical trials employing growth factors for DN have not shown 
beneficial effects [96] except for VEGF [93]. This may reflect the complexities of DN 
extending to treatment in humans in addition to variables such as period, mode, and delivery 
dosage of treatment.
Cell Therapy—As mentioned, emerging evidence have indicated that angiogenic factors 
such as VEGF-A, VEGF-C, SHh, and statin restore microcirculation in the affected nerves 
accompanied by functional improvement [63, 82, 90]. On the other hand, lack of 
neurotrophic factors has been regarded as an important pathogenic mechanism of DN [1, 4]. 
Administration of neurotrophic factors such as NGF [97], IGF1 and IGF2 [36, 37], ciliary 
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neurotrophic factor (CNTF) [98], or glial cell line-derived neurotrophic factor (GDNF) [99] 
was shown to ameliorate DN in animal models.
These findings suggest that a therapeutic modality which can target both angiogenic and 
neurotrophic processes may have more value in treatment of DN. In this sense, cell therapy 
using stem or progenitor cells has advantages over single gene or protein therapy. Cell 
therapy can increase multiple angiogenic and neurotrophic factors and potentially 
supplement specific type of cells required for vascular or neuronal regeneration (Fig. 1). 
Currently, various bone marrow (BM) cells were shown to have favorable effects for 
treating DN. An advantage of using circulating or BM-derived cells is that they can be 
harvested from a patient's own peripheral blood or bone marrow, and re-introduced back to 
the patient [100, 101].
Therapeutic Potential of Bone Marrow Mononuclear Cells: BM-MNCs are derived from 
BM and isolated using density gradient centrifugation. BM-MNCs are heterogeneous cell 
population including lymphocytes, hematopoietic stem/progenitor cells, EPCs and MSCs. 
BM-MNCs have been shown to augment neovascularization by increasing a broad range of 
angiogenic factors, including FGF2, VEGF, and angiopoietin-1 in the tissue [102, 103]. In 
animal models, transplantation of BM-MNCs into ischemic limbs [103] and myocardium 
[102] increased neovascularization and collateral blood vessel formation. These effects of 
BM-MNCs have also been documented in patients with limb ischemia in randomized 
controlled trials [104]. BM-MNCs are easily isolated and do not have to be expanded by ex 
vivo culture. This ease of isolation makes BM-MNCs an attractive source of cells for 
therapeutic neovascularization.
Recent studies have shown favorable therapeutic effects of BM-MNCs on experimental DN. 
Hasegawa and colleagues showed that implantation of either peripheral blood (PB)-MNCs 
or BM-MNCs in a rat model of DN improved motor NCV and blood flow around the sciatic 
nerve, which is possibly mediated by VEGF secreted from MNCs. This study suggests that 
BM-MNCs are more effective than PB-MNCs as BM-MNCs include significantly more 
EPCs than PB-MNCs [81]. Recently Kim et al., reported that intramuscularly transplanted 
BM-MNCs preferentially localize to the nerves in diabetic rats, especially around vasa 
nervorum, and increase expression of various angiogenic and neurotrophic factors in the 
nerves [48]. The vascularity of these nerves improved (Fig. 2) and NCV levels were almost 
normalized [48]. These studies suggest that the vasa nervorum may play a pathogenic role in 
both the development and reversal of DN. This study further suggested that angiogenesis is 
the central mechanism of BM-MNC-induced neovascularization in experimental DN 
because, from their observation, BM-MNCs do not differentiate into, nor fuse with, 
endothelial cells in the nerves at a detectable level.
Therapeutic Potential of Endothelial Progenitor Cells and Postnatal Vasculogenesis: 
The development of vascular system consists of two processes: vasculogenesis and 
angiogenesis. Vasculogenesis refers to the de novo formation of blood vessels from EPCs or 
angioblasts that differentiate into endothelial cells [105], whereas angiogenesis is growth of 
pre-existing vasculature by sprouting of new capillaries through proliferation and migration 
of endothelial cells [106]. Until recently, vasculogenesis was thought to be restricted to 
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embryonic development, while angiogenesis was considered to be responsible for 
neovascularization in embryos and adults. This view was challenged with the discovery of 
BM-derived EPCs, which circulate in adult peripheral blood [107], home to ischemic tissue 
and incorporate into foci of neovascularization [108], leading to de novo blood vessel 
formation.
The identity of EPCs is complicated by the complexity of the definition and various methods 
to define the cells. It is now apparent that different subsets of peripheral or BM derived 
cells, including hematopoietic stem cells, monocytes and circulating endothelial cells, can 
differentiate into endothelial-like cells. BM-derived EPCs in the adult peripheral blood 
express a subset of hematopoietic stem cell markers [109, 110]. Specifically, CD34, CD133 
and VEGF receptor-2 have been proposed as candidate markers for human EPCs [110-112]. 
However, there are no known specific markers to identify EPCs without cultivation. Ex vivo 
expanded human EPCs express various endothelial cells markers such as CD31, CD34, 
KDR, VE-cadherin, bind lectins, and incorporate Dil-acetylated low-density lipoprotein. The 
origin of EPCs is further obscured by the two distinctive types of EPCs arising from 
different culture methods [113]. “Early EPCs”, are mainly derived from mononuclear cells 
or monocytes and do not proliferate after a few weeks [114-116]. On the other hand, “Late 
EPCs” form colonies after more than two weeks in culture, have cobblestone morphology, 
and rapidly proliferate [114, 117]. The distinctive characteristics of these two types of EPCs 
are reinforced by the different expression of cell surface markers. Early EPCs express pan-
leukocyte and monocytic/macrophage markers such as CD45, CD11b and CD14 while late 
EPCs do not. Early EPCs are also therapeutically effective in vivo while evidence for 
therapeutic efficacy of late EPCs are limited to date [114, 117].
Endothelial differentiation of EPCs and whether this differentiation plays a main role in the 
therapeutic benefit of EPCs in recovering damaged tissue function is controversial. Several 
recent studies have demonstrated differentiation of EPCs into endothelial lineage cells with 
incorporation into blood vessels [118, 119]. However, other investigators claim that BM-
derived cells including EPCs do not undergo endothelial differentiation nor incorporate into 
vessel walls [120, 121]. These discrepancies may be due to the difference in cell types, the 
use of different animal models or the rigor criteria to define endothelial differentiation.
One study showed that cord-blood derived EPCs were effective for treating DN [122]. This 
study claimed that mechanistically, the therapeutic effects are due to the increased 
differentiation of EPCs into endothelial cells in hindlimb muscles, which then led to an 
increase in sciatic nerve blood flow. However, this study did not demonstrate the fate of the 
EPCs in tissues, nor did it address the mechanisms by which transplanted EPCs increase 
neovas-cularization in muscles or nerve. Given that most recent studies have argued against 
the endothelial differentiation of EPCs as a major mechanism for neovascularization, 
endothelial differentiation does not appear to underlie such magnitude of therapeutic effects 
toward DN [115, 123].
More recently, a study by the author's group reported that local transplantation of BM-
derived EPCs improved various manifestations of experimental DN through dual angiogenic 
and neurotrophic effects on peripheral nerves (Fig. 1) [47]. This study uncovered some 
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important mechanistic insight into the role of EPCs on DN [47]. First, intramuscularly 
injected EPCs exert therapeutic effects through direct modulation of nerves, not through 
muscular neovascularization. Second, the therapeutic effects of EPCs are mainly mediated 
by humoral or paracrine factors released by EPCs, rather than the direct endothelial 
differentiation of EPCs. Third, the functional capillary (vasa nervora) density in the nerves 
was significantly increased by the EPC treatment. Fourth, Intramuscularly injected EPCs 
preferentially homed to sciatic nerves, characteristically localized in close proximity to vasa 
nervora, and differentiated into endothelial cells albeit infrequently [47]. A large number of 
engrafted EPCs survived in peripheral nerves for more than 12 weeks and induced 
prolonged expression of angiogenic and neurotrophic factors. Fifth, EPC transplantation 
increased proliferation and decreased apoptosis of endothelial and Schwann cells (Fig. 1).
The most notable finding was the direct effect of EPCs on peripheral nerves. The study was 
the first to demonstrate that EPC transplantation increases capillary density and blood flow 
in nerves, suggesting that EPCs induce neovascularization in nerves [47]. The differentiation 
of EPCs into endothelial cells, histologically confirmed as the colocalization of DiI-labeled 
transplanted cells with BS-1 lectin positive endothelial cells was infrequent, suggesting that 
angiogenesis could have played a more important role than vasculogenesis. This neural 
angiogenesis occurred through upregulation of various angiogenic factors in nerves after 
EPC transplantation. Various paracrine factors including VEGF-A [51, 63], FGF2 [124], 
BDNF [42], SHh [59, 82], and stromal cell derived factor (SDF)-1α [125, 126] were 
expressed in the peripheral nerves (Fig. 1). These factors have been shown to have 
synergistic effects on angiogenesis as well as neuro-protecting effects [63, 95, 127]. In fact, 
this study was the first to show clear dual angiogenic and neurotrophic effects of EPCs. This 
upregulation of various classes of biologically important factors may be one of the greatest 
benefits of stem cell therapy over any single protein or gene therapy, enabling the concerted 
efforts of multiple neuro-angiogenic cytokines necessary for neurovascular recovery.
Histologically, the author's study also uncovered novel engraftment and retention 
characteristics of BM-derived cells in tissues [47]. Following a series of reports on the short-
term engraftment of any BM cells in a myocardial infarction model [128, 129], the 
prevailing notion was that adult stem/progenitor cells could not sustain their engraftment 
more than a few weeks. However, the study by Jeong et al., clearly rebutted this notion that 
BM-EPCs could survive more than 12 weeks in nerves [47]. The EPCs which were directly 
injected into the hindlimb muscles disappeared mostly in the muscles within 8 weeks; 
however the EPCs robustly survived for more than 12 weeks in the sciatic nerves. 
Interestingly, the study by Naruse et al., showed that capillary density, which had decreased 
in hindlimb muscles of diabetic rats at 12 weeks of diabetes, was significantly increased 
after cord-blood EPC treatment [122]. However, this study suggested that blood flow and 
capillary density in hindlimb were not significantly changed after EPC treatment. This long-
lasting cell retention is compatible with the observation that EPCs homed to peripheral 
nerves far more preferentially than to muscles. This scale of close interaction between any 
BM cells and steady-state tissues was not previously reported with or without diabetes. The 
long-term retention of EPCs into the nerves in diabetic mice was not expected when we 
started this project. Together, our studies with EPCs or BM-MNCs strongly argue that the 
Kim et al. Page 8
Endocr Metab Immune Disord Drug Targets. Author manuscript; available in PMC 2015 October 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
engraftment characteristics of BM cells depends more on the recipient environment than on 
the transplanted cells themselves [47, 48]. Another intriguing finding was that the engrafted 
EPCs were localized in close proximity to the vasa nervora. Such a large magnitude of 
tropism of BM-derived cells to blood vessels has not been reported in any other tissues. This 
also clearly supports that despite the controversy of EPCs on blood vessel forming capability 
in certain models like myocardial infarction [123, 128, 130], it is evident that EPCs can play 
an important role in vessel homeostasis [123, 131-134]. The distinct properties of BM-
derived EPCs such as peripheral neurotropism, sustained engraftment, and vascular 
localization of EPCs induced robust and prolonged paracrine or humoral effects and reversal 
of various functional and pathologic features of DN [47, 48, 81, 122].
Perspective
DN is a progressive disease and its manifestations can take many years to develop. Cell 
therapy may not be a standard treatment option for all stages of DN because different stages 
of DN are marked by different structural or functional changes. At present, cell therapy may 
be applied to those patients who suffer from intractable symptoms, acute exacerbation, or 
combined diseases such as diabetic foot ulcers or critical limb ischemia.
Practically, as the safety of autologous BM-derived cells has been documented by a number 
of clinical trials [135], it is highly recommended to advance this strategy into a pilot clinical 
trial for those who are severely affected by DN. Particularly, EPCs will be effective in 
treating DN when combined with diabetic wounds or peripheral vascular obstruction as the 
therapeutic effects were already shown in these conditions. However, there are a few 
remaining concerns in cell therapy strategy. First, the effectiveness of the patient's own cells 
needs to be evaluated considering the possibility that BM cells derived from diabetic 
subjects may be impaired in therapeutic potential. Experiments using the autologous cells 
derived from diabetic subjects are necessary to address these concerns. However, although 
the efficacy of autologous diabetic cells is less potent, there may be still ways to overcome 
these defects to a certain extent. One strategy is to enhance their angiogenic and 
neurotrophic effects by culturing cells and activating necessary pathways with small 
molecules or growth factors. Second, the long-term effects of cell therapy need to be tested. 
Given that DN is a disease progressing over a long time, a single injection of cells may not 
be enough to maintain the nerve function over a long period of time. There are a few 
approaches to take in this context. One approach is to implant cells repeatedly to maintain 
their effects. At present, the duration of the beneficial effects of cell therapy in DN is 
unknown and a critical issue that requires further investigation. In many cases, the first 
manifestation of DN is a diabetic foot or ulcer which sometimes requires an amputation and 
a long-term care, which significantly reduces patients' quality of life. Cell therapy in this 
case can be very critical to rescue further tissue loss.
Cardiovascular autonomic neuropathy (CAN) is associated with increased risk of 
cardiovascular morbidity and mortality in diabetic patients [136, 137]. Although CAN is one 
of the most frequently studied complications of diabetes [138] and cell therapy has been 
reported to be effective in improving ischemic cardiovascular disease [132] and peripheral 
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neuropathy, cell therapy has yet been evaluated in either animal models or human patients 
with CAN. Future studies are required to determine the effects of cell therapy in CAN.
Future directions of cell therapy for DN will take steps toward enhancing the potency of 
candidate cells, using both gene and cell therapy, and working with combination of various 
cell types such as those derived from induced pluripotent stem (iPS) cells Once generated, 
iPS cells can offer a plentiful and renewal source of cells that can be induced to differentiate 
into cells of interest [139]. Conclusively, cell therapy may become an innovative alternative 
therapeutic option for treating advanced DN. However, further research is necessary to 
overcome some limitations and possible adverse effects of cell therapy.
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Abbreviations
BDNF Brain-derived neurotrophic factor
BM Bone marrow
DN Diabetic neuropathy
EPC Endothelial progenitor cell
FGF Fibroblast growth factor
IGF Insulin-like growth factor
MNC Mononuclear cell
MSC Mesenchymal stem cell
NCV Nerve conduction velocity
NGF Nerve growth factor NGF
PARP Poly DP-ribose polymerase
PB Peripheral blood
ROS Reactive oxygen species
SHh Sonic hedgehog
VEGF Vascular endothelial growth factor
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Fig. 1. Mechanism of action of various bone marrow-derived cells
Endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) can be cultured 
from mononuclear cells (MNCs). EPCs can differentiate into ECs and MSCs can give rise to 
Schwann cells, astrocytes, and oligodendrocytes. When transplanted into diabetic 
neuropathy animals with injured or ischemic blood vessels, the EPCs and MSCs secret 
angiogenic and neurotrophic factors including VEGF, FGF2, and IGF1, leading to increase 
in Schwann cell proliferation and myelination and decrease in Schwann cell apoptosis.
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Fig. 2. Localization of transplanted EPCs along the vasa nervorum and transdifferentiation of 
EPCs into endothelial cells in nerves
EPCs were isolated from mouse bone marrow and labeled with a red fluorescent dye, CM-
DiI. Streptozotocin-induced diabetic mice were injected with the CM-DiI-labeled EPCs into 
the muscles along the course of the sciatic nerve. Eight weeks after the EPC transplantation, 
the mice hindlimbs were perfused with BM-1 lectin conjugated with FITC to visualize the 
blood vessels and the sciatic nerves were harvested. Whole mounted images of a sciatic 
nerve (A-C) demonstrated that engrafted EPCs (red) preferentially localized along the 
course of the vasa nervorum (green). Bars, 50 μm in B and C.
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